Radiation therapy as part of local control of metastatic neuroblastoma: the St Jude Children's Research Hospital experience.
OBJECTIVE
The purpose of the study was to compare outcomes of pediatric patients with high-risk metastatic neuroblastoma who received radiotherapy (RT) with those of patients who did not.


METHODS
We reviewed the records of 63 patients with newly diagnosed metastatic neuroblastoma treated at our institution (1989-2001) to investigate their characteristics at presentation, dose and field of RT, treatment response, and failure patterns.


RESULTS
Seventeen patients received RT, and 46 did not. In the RT group, a greater percentage of patients had residual disease before consolidation than did those in the no-RT group (88.2% vs 69.6%, P = .008). Gross total resection was achieved less often in the RT group (65% vs 89%, P = .055), but the 5-year cumulative incidences of local failure were similar (35.3% +/- 12.4% vs 32.6% +/- 7.1%). Although there was no difference in 5-year event-free survival, overall survival was better in the no-RT group (47.8% +/- 7.2% vs 23.5% +/- 9.2%, P = .026).


CONCLUSIONS
The addition of RT to the therapy of a group of patients with more residual locoregional disease appeared to improve the local failure rate to approximately that of patients with less residual disease. Radiotherapy may provide even greater benefit to those with less residual disease before consolidation.
Robbins
Jared R
JR
Department of Oncology, St Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
Krasin
Matthew J
MJ
Pai Panandiker
Atmaram S
AS
Watkins
Amy
A
Wu
Jianrong
J
Santana
Victor M
VM
Furman
Wayne L
WL
Davidoff
Andrew M
AM
McGregor
Lisa M
LM
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D009447:Neuroblastoma / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary* / Q000628:therapy; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D016019:Survival Analysis
Clin Cancer Res. 2007 Jul 1;13(13):3942-50
17606728
Cancer. 2005 Dec 15;104(12):2837-46
16288490
Science. 1984 Jun 8;224(4653):1121-4
6719137
J Clin Oncol. 2001 Jan 1;19(1):183-90
11134211
Cancer Lett. 2003 Jul 18;197(1-2):11-7
12880954
J Clin Oncol. 1993 Nov;11(11):2226-33
8229138
J Clin Oncol. 2009 Mar 1;27(7):1007-13
19171716
Pediatr Hematol Oncol. 2003 Mar;20(2):111-7
12554522
J Clin Oncol. 1988 Aug;6(8):1271-9
3411339
J Pediatr Surg. 2004 Jun;39(6):931-6
15185228
Cancer. 2004 Mar 15;100(6):1268-75
15022296
J Clin Oncol. 2003 Apr 15;21(8):1592-601
12697885
J Pediatr Surg. 2004 Mar;39(3):412-7; discussion 412-7
15017562
Nature. 2008 Oct 16;455(7215):975-8
18923525
Eur J Pediatr Surg. 2002 Dec;12(6):402-9
12548494
J Clin Oncol. 2001 Jun 1;19(11):2821-8
11387353
J Pediatr Hematol Oncol. 2002 Nov;24(8):613-21
12439032
Br J Cancer. 1977 Jan;35(1):1-39
831755
J Clin Oncol. 1984 Jul;2(7):719-32
6737018
J Pediatr Hematol Oncol. 2000 May-Jun;22(3):197-205
10864050
J Pediatr Hematol Oncol. 2003 Dec;25(12):934-40
14663275
J Clin Oncol. 1998 Jun;16(6):2169-80
9626218
Int J Radiat Oncol Biol Phys. 2006 Apr 1;64(5):1424-31
16427213
Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):28-39
12694821
J Clin Oncol. 2001 Nov 15;19(22):4189-94
11709561
J Clin Oncol. 1991 Feb;9(2):274-9
1899111
Cancer. 1999 Jul 15;86(2):364-72
10421273
J Clin Oncol. 2007 Mar 20;25(9):1054-60
17369569
Clin Cancer Res. 2006 Mar 15;12(6):1750-9
16551859
J Clin Oncol. 1993 Aug;11(8):1466-77
8336186
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1025-31
11958898
Am J Pathol. 1993 May;142(5):1339-46
7684192
Int J Radiat Oncol Biol Phys. 2000 Mar 1;46(4):969-74
10705019